June 9: The Week in Cancer News
Daily pill lowers lung cancer death rate, the FDA authorizes importing shortage-affected cancer drugs from China, and more.
Progress Against Cancer
Daily pill lowers lung cancer death rate, the FDA authorizes importing shortage-affected cancer drugs from China, and more.
The concept of using vaccination to eradicate cancer by instructing the immune system to eliminate malignant cells has been pursued for decades with little success. Stimulating an immune response against cancer is more complicated...
Clinical trial results suggest patients with high-risk chronic lymphocytic leukemia may benefit from a combination of two targeted therapeutics. Patients with high-risk chronic lymphocytic leukemia (CLL) may benefit from a treatment regimen that combines...
Editor’s note: As we honor National Cancer Survivor Month, we are also recognizing the AACR Scientist↔Survivor Program’s positive impact on survivors during the past 25 years. This story, written by Thomas Celona, first appeared in...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate cancer The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza), in combination with...
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.” — Hippocrates The disease: Glioblastoma, the most lethal form of brain...
High cancer death rates in Native Hawaiian and Pacific Islander communities, and thousands of people lose Medicaid for procedural reasons.
Researchers explore mechanisms of chemotherapy-related neurotoxicity at the AACR Annual Meeting 2023.
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for certain...
Cancer drugs are affected by shortages, and angiogenesis inhibitors make a comeback in combination treatments.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now